報價延遲最少15分鐘:2026/02/28 16:50 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.54 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.56/-0.97
|
|
企業價值
35.96M
|
| 資產負債 |
|
每股賬面淨值
11.94
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
636.00K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Rallybio Corp is a clinical-stage biotechnology company engaged in the development of therapeutic candidates for severe and rare diseases. It focuses on the treatment of conditions related to complement dysregulation and hematologic disorders. The company's flagship program, RLYB116, is a C5 inhibitor being evaluated for potential use in diseases associated with complement dysregulation, including immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody candidate under investigation for the treatment of iron overload disorders. |
